Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 13/20 | 0.55 |
| ▸ | LOX | P28300 | 5/20 | 0.55 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218290 | 0.84 | NOS3 (0.61) | LOXL2LOXCYP1A2POLBNOS3 | |
| SCHEMBL4107151 | 0.84 | LOXL2 (0.61) | LOXL2LOXLOXL3NOS3NOS1 | |
| SCHEMBL15200880 | 0.83 | NOS3 (0.61) | LOXL2LOXLOXL3CYP1A2POLB | |
| SCHEMBL11563922 | 0.82 | NOS3 (0.59) | LOXL2LOXCYP1A2POLBNOS3 | |
| Hydrochloric Acid SCHEMBL5013442 | 0.82 | LOXL2 (0.59) | LOXL2LOXLOXL3NOS3NOS1 | |
| SCHEMBL9817617 | 0.78 | LOXL2 (0.55) | LOXL2LOXLOXL3ROCK1 | |
| Dimethylamine SCHEMBL7744073 | 0.78 | NOS3 (0.55) | CYP1A2POLBNOS3NOS1NOS2 | |
| SCHEMBL16775566 | 0.78 | CYP1A2 (0.47) | LOXL2LOXLOXL3CYP1A2POLB | |
| SCHEMBL2932292 | 0.78 | POLB (0.47) | LOXL2LOXCYP1A2POLBNOS3 | |
| SCHEMBL2935815 | 0.78 | RECQL (0.55) | CYP1A2POLBNOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107759509-A | A kind of synthetic method of tropicamide | 上海泰坦科技股份有限公司 | 2018-03-06 | — | — | CN | claimed |
| CN-106554305-A | A kind of label, its preparation method, labeling method and application | 上海医药临床研究中心 | 2017-04-05 | — | — | CN | claimed |
| US-20250313561-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2025-10-09 | — | — | US | disclosed |
| US-12344606-B2 | Next-generation modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2025-07-01 | — | — | US | disclosed |
| EP-3983078-B1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2023-11-15 | — | — | EP | disclosed |
| EP-3983078-B1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2023-11-15 | — | — | EP | disclosed |
| CN-112592312-B | Preparation method of tropicamide | 无锡济煜山禾药业股份有限公司 | 2022-10-28 | — | — | CN | disclosed |
| US-20220251082-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-08-11 | — | — | US | disclosed |
| WO-2022145982-A1 | TRANSITION METAL COMPLEX CONTAINING TETRADENTATE NITROGEN DONOR LIGAND AND ELECTROCHEMICAL BIOSENSOR COMPRISING SAME | 주식회사 아이센스 | 2022-07-07 | — | — | WO | disclosed |
| EP-3983078-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-04-20 | — | — | EP | disclosed |
| CN-112592312-A | Preparation method of tropicamide | 无锡济煜山禾药业股份有限公司 | 2021-04-02 | — | — | CN | disclosed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004005279-A2 | SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| EP-1056749-A1 | NOVEL TRIAZOLO(4,5-d)PYRIMIDINE COMPOUNDS | AstraZeneca UK Limited (GB) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999041254-A1 | NOVEL TRIAZOLO(4,5-d)PYRIMIDINE COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251082-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | LOXL2 1831/4885LOX 2507/4885LOXL3 1749/4885 |
| US-12344606-B2 | Next-generation modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | LOXL2 1831/4885LOX 2507/4885LOXL3 1749/4885 |
| US-20250313561-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | LOXL2 1831/4885LOX 2507/4885LOXL3 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.